These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 33525941)
1. Pharmacophore-guided repurposing of fibrates and retinoids as GPR40 allosteric ligands with activity on insulin release. Cione E; Caroleo MC; Kagechika H; Manetti F J Enzyme Inhib Med Chem; 2021 Dec; 36(1):377-383. PubMed ID: 33525941 [TBL] [Abstract][Full Text] [Related]
2. Combiphore (Structure and Ligand Based Pharmacophore) - Approach for the Design of GPR40 Modulators in the Management of Diabetes. Gajjar KA; Gajjar AK Curr Drug Discov Technol; 2020; 17(2):233-247. PubMed ID: 30306872 [TBL] [Abstract][Full Text] [Related]
3. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists. Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371 [TBL] [Abstract][Full Text] [Related]
4. CoMFA, CoMSIA and HQSAR Analysis of 3-aryl-3-ethoxypropanoic Acid Derivatives as GPR40 Modulators. Gajjar KA; Gajjar AK Curr Drug Discov Technol; 2020; 17(1):100-118. PubMed ID: 30160214 [TBL] [Abstract][Full Text] [Related]
5. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists. Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Briscoe CP; Peat AJ; McKeown SC; Corbett DF; Goetz AS; Littleton TR; McCoy DC; Kenakin TP; Andrews JL; Ammala C; Fornwald JA; Ignar DM; Jenkinson S Br J Pharmacol; 2006 Jul; 148(5):619-28. PubMed ID: 16702987 [TBL] [Abstract][Full Text] [Related]
7. Structure-Activity Relationship Study and Biological Evaluation of 2-(Disubstituted phenyl)-indole-5-propanoic Acid Derivatives as GPR40 Full Agonists. Zhao X; Yoon DO; Yoo J; Park HJ J Med Chem; 2021 Apr; 64(7):4130-4149. PubMed ID: 33769827 [TBL] [Abstract][Full Text] [Related]
9. PPAR-γ activation increases insulin secretion through the up-regulation of the free fatty acid receptor GPR40 in pancreatic β-cells. Kim HS; Hwang YC; Koo SH; Park KS; Lee MS; Kim KW; Lee MK PLoS One; 2013; 8(1):e50128. PubMed ID: 23372643 [TBL] [Abstract][Full Text] [Related]
10. Ginseng Gintonin Contains Ligands for GPR40 and GPR55. Cho YJ; Choi SH; Lee R; Hwang H; Rhim H; Cho IH; Kim HC; Lee JI; Hwang SH; Nah SY Molecules; 2020 Mar; 25(5):. PubMed ID: 32121640 [TBL] [Abstract][Full Text] [Related]
11. Evidence for the involvement of GPR40 and NADPH oxidase in palmitic acid-induced superoxide production and insulin secretion. Graciano MF; Valle MM; Curi R; Carpinelli AR Islets; 2013; 5(4):139-48. PubMed ID: 23817296 [TBL] [Abstract][Full Text] [Related]
13. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Srivastava A; Yano J; Hirozane Y; Kefala G; Gruswitz F; Snell G; Lane W; Ivetac A; Aertgeerts K; Nguyen J; Jennings A; Okada K Nature; 2014 Sep; 513(7516):124-7. PubMed ID: 25043059 [TBL] [Abstract][Full Text] [Related]
14. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals. Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026 [TBL] [Abstract][Full Text] [Related]
15. Structural basis for GPR40 allosteric agonism and incretin stimulation. Ho JD; Chau B; Rodgers L; Lu F; Wilbur KL; Otto KA; Chen Y; Song M; Riley JP; Yang HC; Reynolds NA; Kahl SD; Lewis AP; Groshong C; Madsen RE; Conners K; Lineswala JP; Gheyi T; Saflor MD; Lee MR; Benach J; Baker KA; Montrose-Rafizadeh C; Genin MJ; Miller AR; Hamdouchi C Nat Commun; 2018 Apr; 9(1):1645. PubMed ID: 29695780 [TBL] [Abstract][Full Text] [Related]
16. GPR40: a therapeutic target for mediating insulin secretion (review). Feng XT; Leng J; Xie Z; Li SL; Zhao W; Tang QL Int J Mol Med; 2012 Dec; 30(6):1261-6. PubMed ID: 23023155 [TBL] [Abstract][Full Text] [Related]
17. GPR40-Mediated G Rives ML; Rady B; Swanson N; Zhao S; Qi J; Arnoult E; Bakaj I; Mancini A; Breton B; Lee SP; Player MR; Pocai A Mol Pharmacol; 2018 Jun; 93(6):581-591. PubMed ID: 29572336 [TBL] [Abstract][Full Text] [Related]
18. Structural basis for the agonist action at free fatty acid receptor 1 (FFA1R or GPR40). Rodrigues DA; Pinheiro PSM; Ferreira TTDSC; Thota S; Fraga CAM Chem Biol Drug Des; 2018 Mar; 91(3):668-680. PubMed ID: 29068547 [TBL] [Abstract][Full Text] [Related]
19. Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40. Schnell S; Schaefer M; Schöfl C Mol Cell Endocrinol; 2007 Jan; 263(1-2):173-80. PubMed ID: 17101212 [TBL] [Abstract][Full Text] [Related]
20. GPR40 protein levels are crucial to the regulation of stimulated hormone secretion in pancreatic islets. Lessons from spontaneous obesity-prone and non-obese type 2 diabetes in rats. Meidute Abaraviciene S; Muhammed SJ; Amisten S; Lundquist I; Salehi A Mol Cell Endocrinol; 2013 Dec; 381(1-2):150-9. PubMed ID: 23911664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]